key: cord-0428192-g1vdpc6g authors: Ashford, F.; Best, A.; Dunn, S.; Ahmed, Z.; Siddiqui, H.; Melville, J.; Wilkinson, S.; Mirza, J.; Cumley, N.; Stockton, J.; Ferguson, J.; Wheatley, L.; Ratcliffe, E.; Casey, A.; The COVID-19 Genomics UK Consortium5,; Quick, J.; Richter, A.; Loman, N. J.; McNally, A. title: SARS-CoV-2 testing in the community: Testing positive samples with the TaqMan SARS-CoV-2 Mutation Panel to find variants in real-time date: 2021-11-21 journal: nan DOI: 10.1101/2021.11.17.21266297 sha: 3f803752e97d2095f3b7f8a3fec18c136b2b2750 doc_id: 428192 cord_uid: g1vdpc6g Genome sequencing is a powerful tool for identifying SARS-CoV-2 variant lineages, however there can be limitations due to sequence drop-out when used to identify specific key mutations. Recently, Thermo Fisher Scientific have developed genotyping assays to help bridge the gap between testing capacity and sequencing capability to generate real-time genotyping results based on specific variants. Over a 6-week period during the months of April and May 2021, we set out to assess the Thermo Fisher TaqMan Mutation Panel Genotyping Assay, initially for three mutations of concern and then an additional two mutations of concern, against SARS-CoV-2 positive clinical samples and the corresponding COG-UK sequencing data. We demonstrate that genotyping is a powerful in-depth technique for identifying specific mutations, an excellent complement to genome sequencing and has real clinical health value potential allowing laboratories to report and action variants of concern much quicker. Over a 6-week period during the months of April and May 2021, we set out to assess the Thermo 23 Fisher TaqMan Mutation Panel Genotyping Assay, initially for three mutations of concern and then an 24 additional two mutations of concern, against SARS-CoV-2 positive clinical samples and the 25 corresponding COG-UK sequencing data. We demonstrate that genotyping is a powerful in-depth 26 technique for identifying specific mutations, an excellent complement to genome sequencing and has 27 real clinical health value potential allowing laboratories to report and action variants of concern much 28 quicker. 29 Keywords: SARS-CoV-2, variants of concern, genotyping, genome sequencing, real-time, SNPs 30 31 . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. Previously at the University of Birmingham, we set up a SARS-CoV-2 modular testing facility at the 47 request of the United Kingdom Department of Health and Social Care (6). Our PCR assay of choice was 48 the 3-target design (ORF1ab, S and N genes) TaqPath COVID-19 CE-IVD RT PCR Kit, where target areas 49 are unique to SARS-CoV-2 to reduce detection of other coronaviruses and compensate for virus 50 mutations. Initially, we detected all three genes in SARS-CoV-2 samples, however, during November 51 2020, we along with other laboratories using the same PCR assay, started to notice a drop-off in the 52 detection of the S-gene and then a rapid rise in this S-gene target failure (SGTF) in early December 53 2020 (7). From discussions with the University of Birmingham genome sequencing laboratory (as part 54 of the COG-UK Consortium) and as confirmed by other laboratories, it was demonstrated that S-gene 55 did amplify, therefore confirming this gene was still present, but was not being detected using the 56 . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint To better understand viral transmission and evolution and to inform public health responses and 67 vaccine development, genomic sequencing is essential. In March 2020, the COVID-19 Genomics UK 68 Consortium (COG-UK) was created for this purpose (10) . To date, COG-UK have sequenced over 69 1,100,000 SARS-CoV-2 samples, providing a vast amount of data to the global COVID-19 response. This 70 yields crucial information about the number of variants circulating in the population and possible lines 71 of transmission, however, sequencing can be timely, costly and in some cases full coverage of the virus 72 is not possible. 73 Recently, Thermo Fisher have developed genotyping assays to help bridge the gap between testing 74 capacity and sequencing capability to receive results in real-time, so in addition to our modular system 75 for COVID-19 testing, we decided to build into our work-flow the Thermo Fisher TaqMan TM SARS-CoV-76 2 mutation panel ( Figure 1 ). Here we present our data showing that the TaqMan genotyping assays 77 identify variants in all samples tested with zero failure rate, and that often the assay confirms 78 mutations in a viral isolate that cannot be definitively identified from genome sequence data alone. 79 We conclude that the genotyping assay is an excellent complement to genome sequencing efforts and 80 . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The ARTIC network "nCoV-2019 novel coronavirus bioinformatics protocol" (16) was used to process 144 the raw sequencing data including genome assembly and variant calling using nanopolish 0.11.3 (17). 145 The genotyping was then performed using a nextflow pipeline 146 (https://github.com/BioWilko/genotyping-pipeline). Briefly; genotypes were called using aln2type 147 (https://github.com/connor-lab/aln2type) utilising custom variant definition files for each mutation 148 (included in repository), and lineages were called using Pangolin (18) . 149 . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Figure 3A ), thus allowing for clear and simple classification of results. 160 Each probe is labelled with VIC dye to detect the reference (WT) sequence and FAM dye to detect the 161 mutation sequence, which has one nucleotide difference. This allows clear discrimination on a cluster 162 plot between WT and mutation samples, as seen with the AcroMetrix control (reference sequence) 163 and plasmid control containing the mutation sequence, Figure 3B . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint the NTCs, thus exhibiting weak amplification due to the probes non-specific activity, Figure 3C . 175 Genotyping calls can manually be adjusted to 'no amp', or two separate assays run such as P681R and 176 P681H to compare and facilitate accurate genotype analysis. If it is not possible to make a call, then 177 further characterisation by genome sequencing would be necessary. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.17.21266297 doi: medRxiv preprint All samples run through the mutation panel assay produced a result, with either mutation present, 188 absent or reference/mutation, indicating another mutation within that SNP was present. Input 189 samples had varying Ct values (Ct 12-29) with regards to each of the three single-target genes Orf1ab, 190 N gene and S gene (Supplementary data 1) . Using the Orf1ab gene as marker for Ct distribution across 191 a Ct value group, good distribution of different Ct values was observed (Figure 4 ). RNA quality was not 192 measured, and in some cases, samples had been stored at -80°C for up to 2 months and through no 193 more than 2 freeze/thaw cycles. However, no effect on the performance of the mutation assay was 194 observed. Furthermore, we also noted that for positive samples Ct ≤18 RNA was added at 2.5ul instead 195 of 5ul into the Mutation Panel PCR reaction, therefore, allowing more RNA to be archived. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.17.21266297 doi: medRxiv preprint that of genome sequencing. By cross referencing the genome sequencing results for each SNP we 203 could identify whether the mutation assay correctly calls each SNP mutation. Our data shows that for 204 all samples, where sequencing data was available, the mutation panel is in 100% agreement ( Figure 205 45A -Also refer to Supplementary Data 1 for complete data set for all samples run). While Nanopore 206 sequencing may miss a SNP mutation (Figure 5B ), the mutation assay can identify this. This is likely 207 due to the RNA quality and platform used for sequencing, but highlights the importance of the 208 genotyping assay for rapid identification and subsequent action. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.17.21266297 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.17.21266297 doi: medRxiv preprint clarification from the University of Birmingham arm of the COG UK consortium confirmed that this 229 was a small cluster of B1.1.7 variants that was being monitored and actioned in the Birmingham area. 230 The mutation panel designed for this assay was to identify samples containing SNPs associated with 232 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 1.617.2) . 269 Here we demonstrate that these mutation panels provide robust detection of VOC even if RNA is of 270 low quality and after more than one freeze/thaw step. Importantly, a specific mutation can be 271 identified on the same day that a nasopharyngeal swab tests positive by RT-PCR. Where sequencing 272 data was available, the genotyping assay always matched 100% to the correct lineage. 273 The ref/mut function is a key to the genotyping assay as when detected this will imply an amino acid 274 change for the specific mutation at the genomic site where the primers amplify. This is crucial in 275 alerting to the potential rise of a new VOI (variants of interest) so it can be monitored to see its 276 potential to become a VOC. 277 Our study confirms that same day rapid real-time detection of variants present in the population is 278 very achievable -from a swab entering the lab, processing through the TaqPath COVID-19 RT-PCR and 279 mutation assay, where results were then available in approximately 5 hours. Confirmation of 280 mutations present and lineage identification following genomic sequencing on-site was provided in 281 approximately 72hours, however, when on-site sequencing is not available this may increase 282 turnaround time significantly. Rapid identification of VOCs enables test-and-trace to identify regional 283 clusters and perform targeted testing to prevent spread of more transmissible variants. Having both 284 PCR set-ups in our modular testing system and on-site sequencing removes the logistics, costs and 285 time of moving samples between testing labs and sequencing labs and reporting the results. 286 Importantly, the genotyping panel can be updated readily as new SNP mutations are identified via 287 genome sequencing data from COG-UK. Delta variants emerged quickly over a few weeks and during 288 . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.17.21266297 doi: medRxiv preprint our study we were able to source very quickly, two mutation panels for the Delta variant (L452R and 289 P681R) and on arrival were able to action on the same day. 290 Genome sequencing can be inconclusive for identifying key mutations found by the mutation panels 291 but nonetheless, it is a powerful tool for identifying SARS-CoV-2 variant lineages through phylogenetic 292 trees. However, previous studies have discussed there are limitations due to sequence drop-out when 293 used to identify specific key mutations (18, 19, 20, 21) . Nanopore sequenced long-reads can be 294 susceptible to errors where identifying specific mutations may be problematic. These allelic drop-outs 295 potentially affect PCR-based (tile amplicon) targeted sequencing, thus resulting in incomplete genome 296 coverage, especially at lower amounts, resulting in the loss of both 5' and 3' regions that fall outside 297 primer binding positions. The presence of SNPs in the forward and / or reverse primer binding sites 298 may lead to complete or partial lack of amplification. 299 For the study presented here, we demonstrated that genotyping has two major functions. 1) 300 Genotyping is a powerful additional, more in-depth assay for identifying specific mutations and has 301 real clinical health value allowing laboratories to report and action VOC much quicker than genome 302 sequencing. 2) Genotyping is an excellent additional complement to the already powerful tool of 303 genome sequencing already proven for assigning lineages via phylogenetic trees. 304 Our data confirms that SARS-CoV-2 genotyping is essential for real-time identification of VOC here 305 now and tracking those that emerge for informing public health strategy. 306 Reagents and technical assistance for this study were provided free of charge by Jelena Feenstra, 308 Tamra Hill and Manoj Ghandi at Thermo Fisher. Thermo Fisher had no influence or role in study design, 309 data analysis, data interpretation or construction of the manuscript. The UoB Turnkey Covid diagnostic is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.17.21266297 doi: medRxiv preprint COVID-19 Genomics UK (COG-UK). An integrated national scale SARS-CoV-2 genomic surveillance 339 network MagMAX Viral/Pathogen II Nucleic Acid Isolation Kit ThermoFisher TaqPath COVID-19 RT-PCR testing kit ARTIC Network. ARTIC Nanopore protocol for nCoV2019 novel coronavirus nCoV-2019 novel coronavirus bioinformatics protocol ARTICnetwork 2020 Significantly Higher Viral Load in Samples Tested by TaqPath Polymerase Chain Reaction Real-time, portable genome sequencing for Ebola 357 surveillance Highly accurate-single chromosomal complete 359 genomes using IonTorrent and MinION sequencing of clinical pathogens . CC-BY 4.0 International license It is made available under a perpetuity.is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintThe copyright holder for this this version posted November 21, 2021. ; https://doi.org/10.1101/2021.11.17.21266297 doi: medRxiv preprint